SEC Form 4 · accession 0001209191-19-017738

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Scott Biller

Officer — Chief Scientific Officer

Period of report

Mar 5, 2019

Accepted (ET)

Mar 7, 2019 · 4:06 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001439222

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common stock	Mar 5, 2019	M	428	$31.64	A	26,939	D
Common stock	Mar 5, 2019	M	2,572	$39.76	A	29,511	D
Common stock^F3	Mar 5, 2019	S	200	$66.45	D	29,311	D
Common stock^F4	Mar 5, 2019	S	2,600	$67.73	D	26,711	D
Common stock^F5	Mar 5, 2019	S	200	$68.22	D	26,511	D
Common stock^F6	holding	—	—		—	53,059	I	See footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock option (right to buy)^F7	$31.64	Mar 5, 2019	M	428	D	—	Mar 4, 2024	Common stock	428	11,354	D
Stock option (right to buy)^F8	$39.76	Mar 5, 2019	M	2,572	D	—	Feb 15, 2026	Common stock	2,572	42,648	D

Explanation of responses

F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $66.05 to $66.85. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $67.14 to $68.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $68.14 to $68.30. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F6Shares held by a spousal lifetime access trust, of which the reporting person's wife is the trustee.
F7This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F8This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.